Literature DB >> 32651819

Experience of Using Tripeptide Leu-Ile-Lys for Experimental Therapy of Chronic 16-Week Oxalate Nephrolithiasis in Rats.

A Yu Zharikov1, N N Yakushev2, O N Mazko2, O G Makarova2, A V Lepilov2, I P Bobrov2, G V Zharikova2, V I Kiselev2.   

Abstract

We studied the effect of tripeptide Leu-Ile-Lys on the course of chronic 16-week oxalate nephrolithiasis in rats modeled by administration of 1% ethylene glycol solution in drinking water for 16 weeks. The tripeptide Leu-Ile-Lys obtained by chemical synthesis (sample purity ≥98%) was administered intragastrically through a probe in a dose of 11.5 mg/kg in 1 ml saline. It was found that during tripeptide Leu-Ile-Lys significantly alleviated the course of experimental pathology, which was confirmed by characteristic biochemical and morphological indicators. We observed a decrease in the concentration of calcium ions by 4.4 times, weakening of oxidative stress in the renal tissue due to a decrease in the total prooxidant activity by 1.2 times, normalization of increased catalase activity, and reduction of superoxide dismutase activity by 2.4 times relative to disease control. Histological signs of nephrolithiasis were recorded in 9% cases (vs. 75% cases in disease control).

Entities:  

Keywords:  experimental oxalate nephrolithiasis; tripeptide Leu-Ile-Lys

Mesh:

Substances:

Year:  2020        PMID: 32651819     DOI: 10.1007/s10517-020-04858-x

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  1 in total

1.  Nephroprotective Effect of Leu-Ile-Lys Tripeptide in Experimental Diabetes Mellitus.

Authors:  G V Zharikova; A Yu Zharikov; O N Mazko; O G Makarova; I P Bobrov; A S Kalnitsky
Journal:  Bull Exp Biol Med       Date:  2022-06-23       Impact factor: 0.804

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.